【ASCO-GU 2025】四川大学华西医院首战告捷

NatureBoy

7 V; v- I. W7 O  |8 ]
4 B1 o' H; z7 Y; ^2025年美国临床肿瘤学会-泌尿生殖系统癌症研讨会（ASCO-GU 2025）摘要标题公布，初步统计了下，可能稍有误差，牵头入选成果数
- [* q+ t. d" V+ a5 e% k: l; }" ]' Q4 d川大华西医院 25项
& K5 _, @, u$ h& M中山大学系统 8项（肿瘤医院6项、第一医院1项、孙逸仙医院1项）
. F+ ?! R1 A1 S5 s- B北京大学系统 7项（肿瘤医院5项、第一医院2项）
中国医科院系统 7项（肿瘤医院7项）
& d8 Y5 W+ b3 P$ j5 K. E上海交大系统 6项（仁济医院5项、瑞金医院1项）
" l% M/ w0 p; R; d复旦大学系统 5项（肿瘤医院5项）
& e* U# A6 D, ], |*大会收录摘要总数886项
& M4 h6 L" o; n- o/ |* ~  }$ x" Y

不流川

厉害！华科有无？

NatureBoy

不流川 发表于 2025-1-9 16:03
厉害！华科有无？

查到有参加3项复旦肿瘤牵头的国内多中心研究

NatureBoy

! S9 L; `1 G* ~3 t2 a0 v
1 m; A3 |; t& n2 O华西医院泌尿肿瘤近年算是快速回春了，一年期内成绩单
2 k+ L) x5 d& D复旦版2023泌尿外科临床专科声誉 并列第2
医科院版2023泌尿外科科技量值 第1
医科院版2019-2023泌尿外科五年期科技量值 第1
ASCO-GU 2024、2025 第1
3 ~5 |/ Y0 X* Y2 G- IASCO 2024泌尿肿瘤相关部分 第1
6 _" m; }; X$ G% b$ `+ LEAU 2024 第1
ICS 2024 第1
& t6 n/ I% m" K
3 {8 U. ]1 m5 U* `" ^1 ]

! U' n8 `# s! s1 V

不流川

NatureBoy 发表于 2025-1-9 16:07
( M6 E$ A/ s' _" Q5 n, X: h查到有参加3项复旦肿瘤牵头的国内多中心研究

" [" k& |6 E; Y( y4 w) i0 l谢谢！

whoknowsname

在没有肿瘤专科医院的情况下有这成绩很不错

NatureBoy

还统计少了，华西医院牵头是25项
01.Risk factors of complications after inguinal lymph node dissection in patients with penile cancer.
02.Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor.
5 }2 I8 b+ l1 ?: c% A, d' l- ~03.Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity.
% `  o0 V8 R4 ]1 Z, s$ \) v0 M04.The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer.
05.Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
06.Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy.
. Q# W- |5 j5 Y3 J/ W5 M6 D07.Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines.
; V. k3 N$ ]( K# S08.Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.
09.Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
8 e/ r$ a# t- K! w( j' I2 l: F8 W3 C10.Interpretable machine learning for prostate biopsy: Cohort study.
11.Genomic features of prostate cancer patients with and without ductal adenocarcinoma (DA) based on liquid biopsy.
12.Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
13.Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).
14.A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03).
- V6 b. x' W3 G+ p) |  `15.VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy.
* y6 ~) a9 O) V& `1 b! `8 n6 [$ L16.Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
17.Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors.
- H1 G: }0 Q1 D2 F. A8 _18.Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.
19.Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis.
20.The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.
* T; P9 X- p' Q( V3 G21.Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021.
22.Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis.
' h% }' B! {3 ^2 T5 e23.Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario.
24.The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
7 F# l; F0 O2 g6 }$ q3 p25.Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.
7 t: X/ e* W# P; m; L- F

NatureBoy

; _* M& F9 V8 e

whoknowsname 发表于 2025-1-9 17:01
在没有肿瘤专科医院的情况下有这成绩很不错

) s* m4 \3 s8 d: h% J7 L泌尿肿瘤赛道算不错，国内牵头成立CUDA-UTUC协作组、CUDA肾上腺高血压外科协作组、CACA-GU少见肾癌协作组等三个协作组，其他赛道还是干不过肿瘤专科医院，兄弟单位们都很强 看年内重离子质子医院投运后，能否发起追赶

whoknowsname

NatureBoy 发表于 2025-1-9 17:34
泌尿肿瘤赛道算不错，国内牵头成立CUDA-UTUC协作组、CUDA肾上腺高血压外科协作组、CACA-GU少见肾癌协作组 ...

6 t/ y/ }7 D6 t3 W  Q复旦榜的肿瘤专科声誉排行榜的前十里非肿瘤专科的也只有华西了

NatureBoy

whoknowsname 发表于 2025-1-9 17:57
( E( U3 ?/ U: c, C3 B复旦榜的肿瘤专科声誉排行榜的前十里非肿瘤专科的也只有华西了

- E( f1 w8 q. y8 k/ m) Z同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该是中山或者医科院。

whoknowsname

NatureBoy 发表于 2025-1-9 18:33
同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该 ...

. S* W, C9 N* _# I7 l哦豁？居然不是北肿？

whoknowsname

NatureBoy 发表于 2025-1-9 18:33
同期的ASCO GI表现太拉，我都不好意思发，对应的华西医院腹部肿瘤病房发展明显落后了，GI表现最好的应该 ...

8 H3 r% S$ S4 [; v; G1 r* R不过你们腹部肿瘤科的介入做的挺不错吧

cnseiaus

大华西厉害